Enflonsia (Clesrovimab-cfor)

Enflonsia (clesrovimab-cfor) is a respiratory syncytial virus (RSV) F protein-directed fusion inhibitor used for the prevention of RSV lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season.

Recommended Dosage:
The recommended dose for neonates and infants born during or entering their first RSV season is 105 mg administered as a single intramuscular (IM) injection. For neonates and infants born during the RSV season, administer this therapeutic drug once starting from birth. For infants born outside the RSV season, administer the medicine once before the start of their first RSV season, considering the duration of protection provided by treatment.

Infants Undergoing Cardiac Surgery with Cardiopulmonary Bypass: For infants undergoing cardiac surgery with cardiopulmonary bypass during or entering their first RSV season, an additional 105 mg dose administered as an IM injection is recommended as promptly as the infant is stable after surgery to ensure adequate clesrovimab-cfor serum levels.

• Life-threatening allergic reactions may occur. Monitor patients throughout and after the injection. Manage anaphylaxis with epinephrine and supportive measures. In case signs of hypersensitivity occur, stop administration promptly. Do not restart in those with serious allergic events. Report all reactions to the healthcare provider (HCP).
• Administration of Clesrovimab‑cfor may interfere with RSV diagnostic assays. False positive or false negative results can occur because of antibody cross‑reactivity. Let laboratory personnel know about the recent infusion. Use alternative diagnostic methods in case required. Interpret test results with caution. Continue to monitor the patient based on clinical signs.
• Use of Clesrovimab‑cfor injection in pregnancy should be limited to those with clinical need. Available animal findings have not demonstrated potential fetal harm. Women should inform their healthcare provider (HCP) if pregnancy occurs during treatment. Monitor mother and fetus for side effects. Weigh risks versus benefits.
• Lactating women should use this medicine only if clearly required. It is unknown if the medicine is excreted in human milk. Monitor infants for reactions such as diarrhea, rash, or infection. Consider the benefits of breastfeeding versus potential risks from drug exposure when deciding to treat.
• The safety and effectiveness of this medicine in pediatric patients have not been established. Do not use it in children under 12 years. Limited clinical findings are available in adolescents. If prescribing for older pediatric patients, monitor growth as well as development. Promptly report any unexpected side effects to the manufacturer.

What documents are required to import ENFLONSIA to India?

ENFLONSIA (clesrovimab-cfor) injection can be imported by patients or government hospitals in the name of the patients only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is ENFLONSIA available in India?

ENFLONSIA (clesrovimab-cfor injection) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On availability of Enflonsia in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada,
• Europe, and Australia
• Ensuring 100% transparency.

ENFLONSIA can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of ENFLONSIA (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Enflonsia 105 mg/0.7 mL injection price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source ENFLONSIA (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient's address only from New Delhi, India.

What is the Generic Name for the trade name drug Enflonsia®?

Clesrovimab-cfor is the Generic Name for the trade name drug Enflonsia®.

What is the Manufacturer's Name of Enflonsia®?

Enflonsia® is manufactured by Merck Sharp & Dohme LLC.

Is Enflonsia approved by the FDA?

Yes, Enflonsia is approved by the FDA. Date of first approval: June 9, 2025.

What is the dosage and form of Enflonsia® supplied?

Enflonsia is supplied for Injection: 105 mg/0.7 mL in a single-dose prefilled syringe for intramuscular (IM) use.

What are the most common side effects of Enflonsia® 105 mg/0.7 mL injection?

The most common side effects of Enflonsia® are injection-site erythema, injection-site swelling, and rash.

How much does Enflonsia® 105 mg/0.7 mL injection cost in India?

Enflonsia® is not yet approved in India. However, patients in India can legally access it through the provision called the Named Patient Program (NPP). Prices of Enflonsia injection may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Enflonsia 105 mg/0.7 mL cost in India, please call/WhatsApp +91-9310090915 or send an email to info@indianpharmanetwork.in.

Can Enflonsia® 105 mg/0.7 mL injections be available in SAARC countries?

Apart from Gulf countries, Enflonsia® can be accessed through import provisions like the Named Patient Program (NPP) in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Enflonsia® injection in these countries. We help provide legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Enflonsia® 105 mg/0.7 mL injection online in India?

Yes, one can buy Enflonsia 105 mg/0.7 mL online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not yet registered or available in their country. We can help facilitate the legal supply of Enflonsia® injection through legal channels.

What are the storage conditions of Enflonsia® 105 mg/0.7 mL injections?

Store prefilled syringes under refrigeration at 36°F to 46°F (2°C to 8°C). Keep the prefilled syringe in the original carton to protect it from light until the time of use. Neither freeze nor shake it.